Shane Cooke - Oct 10, 2022 Form 4 Insider Report for PROTHENA CORP PUBLIC LTD CO (PRTA)

Role
Director
Signature
/s/ Michael Malecek, as Attorney in Fact for Shane M. Cooke
Stock symbol
PRTA
Transactions as of
Oct 10, 2022
Transactions value $
-$247,500
Form type
4
Date filed
10/12/2022, 09:45 PM
Previous filing
Sep 30, 2022
Next filing
Nov 10, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PRTA Ordinary Shares, par value $0.01 per share Options Exercise $32.1K +5K $6.41* 5K Oct 10, 2022 Direct
transaction PRTA Ordinary Shares, par value $0.01 per share Sale -$129K -2.32K -46.48% $55.37 2.68K Oct 10, 2022 Direct F1, F2
transaction PRTA Ordinary Shares, par value $0.01 per share Sale -$151K -2.68K -100% $56.38 0 Oct 10, 2022 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PRTA Stock Option (Right to Buy) Options Exercise $0 -5K -25% $0.00 15K Oct 10, 2022 Ordinary Shares 5K $6.41 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
F2 The transaction was executed in multiple trades in prices ranging from $54.855 to $55.85, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the ranges set forth in footnotes 2 and 3 of this Form 4.
F3 The transaction was executed in multiple trades in prices ranging from $56.01 to $56.96, inclusive.
F4 The option was granted on January 29, 2013, and all shares subject to the option were fully vested and exercisable January 29, 2014. The option will expire in approximately four months and be forfeited to the extent it is not exercised on or prior to January 29, 2023.